Showing results (291-300 of 2,509) with videos related to

Sort By:
Pageof 251
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2015
How Center Volumes Affect Early Outcomes in Acute Myeloid LeukemiaAndrew W Hahn, Omer Jamy, Sara Nunnery, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 13, 2015
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United StatesMartin Tallman, Francesco Lo-Coco, Gisoo Barnes, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2015
Treatment Outcomes in CML Patients Treated With Tyrosine Kinase Inhibitors at a Tertiary Teaching Hospital in South AfricaGerhard Sissolak, Jacques Badenhorst, Janami Steenkamp, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2015
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple MyelomaPierre Squifflet, Stefan Michiels, David Siegel, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2015
Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion ProductNeelima Vidula, Marcelo Villa, Irene B Helenowski, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Role of Surveillance Imaging in Patients With Peripheral T-Cell LymphomaTiffany Tang, Zhengming Chen, Pannee Praditsuktavorn, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2016
Comorbidities Drive Outcomes for Both Malignancy-Associated and Non-Malignancy-Associated Hemophagocytic SyndromeBenny Johnson, Smith Giri, Sara E Nunnery, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2015
The Role of β-Catenin in Bcr/Abl Negative Myeloproliferative Neoplasms: An Immunohistochemical StudyAyfer Geduk, Elif B Atesoglu, Pinar Tarkun, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2015
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in AustriaGregor Aschauer, Richard Greil, Werner Linkesch, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 7, 2015
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before AzacitidineAmer M Zeidan, Najla H Al Ali, Eric Padron, et al.
Pageof 251